查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750862

預測性生物標記市場規模、佔有率、趨勢分析報告：適應症、技術、地區、細分市場預測，2025-2030

Predictive Biomarkers Market Size, Share & Trends Analysis Report By Indication, By Technology (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

預測性生物標記市場摘要

預計 2024 年全球預測生物標記市場規模為 243 億美元，到 2030 年將達到 635.4 億美元，2025 年至 2030 年的複合年成長率為 18.02%。由於基因組學和精準醫療的進步、研發投資的增加以及對早期檢測和個人化治療的需求不斷成長等多種因素，該市場正在經歷顯著成長。

研發是預測性生物標記市場成長的主要驅動力，它促進了創新和新候選生物標記的發現。基因組學和精準醫療處於醫療技術的前沿，為更有針對性和更有效的治療提供了潛力。干預效果的預測性生物標記可以反映個體的生物成分（「宿主特徵」），或與疾病過程和其他病理相關的特徵。英國國家醫療服務體系 (NHS) 和政府正在大力投資這些技術，包括推出 NHS 基因組醫學服務。該服務致力於推動基因組學發展，造福患者，包括進行基因組序列測定、為癌症患者提供分子診斷和基因檢測，以及增強數據整合以推動更有效的治療。此外，透過合作，我們累積了技術和數據分析的專業知識，並在開發新型定序技術方面擁有深厚的專業知識，這些專業知識能夠推動創新和有效治療。

例如，2025年4月，Ilmunia與Tempus AI合作，加速向患者推出次世代定序檢測。

研發投入的增加是預測性生物標記市場的主要驅動力。製藥公司、生技公司和學術機構正投入大量資源來發現新的生物標記並推動診斷技術的發展。生物標記辨識的主要應用之一是次世代定序儀(NGS)，它可以快速檢測基因內數百萬個 DNA 拷貝。該技術能夠在短時間內對多個基因和突變進行全面分析。例如，Illumina 的 NovaSeq X 平台提供高通量定序，用於數據分析和疾病診斷。生物標記發現領域的資金投入和合作不斷增加，促進了更有效、更準確的預測測試的發展。這正在加速預測性生物標記市場的成長，並支持下一代醫療保健創新。

對疾病早期檢測和個人化治療的需求不斷成長，是預測性生物標記市場的主要驅動力之一。生物標記能夠提供關於個人健康狀況的寶貴見解，並有助於在症狀出現之前的早期識別疾病。早期檢測可以實現更有效的干涉，改善患者預後並降低治療成本。預測性生物標記的一個關鍵應用領域是腫瘤學，其中抗治療性的跡象（這仍然是乳癌患者死亡的主要促進因素）推動了對預測性生物標記開發的需求。

人們正在研究體學技術和人工智慧等創新方法，以識別高度精準的分子和成像生物標記物，從而有可能改善治療效果。生物標記物正越來越普遍地被納入臨床試驗，用於安全性和有效性研究。預測性生物標記物也可能成為臨床試驗的一部分，以根據患者需求客製化藥物。隨著醫療保健系統向個人化醫療轉變，預測性生物標記將在最佳化治療方法和確保每位患者獲得正確治療方面發揮關鍵作用。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 預測性生物標記市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 預測生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章預測生物標記市場：適應症估計與趨勢分析

  • 細分儀表板
  • 預測性生物標記市場：變異分析
  • 預測生物標記市場規模和趨勢分析（2018-2030）
  • 預測生物標記市場收益估計和預測（2018-2030）
  • 癌症
  • 心血管疾病
  • 神經系統疾病
  • 免疫疾病
  • 其他

第5章預測生物標記市場：技術評估與趨勢分析

  • 2024年及2030年的市場佔有率
  • 細分儀表板
  • 全球預測生物標記市場前景
  • 市場規模、預測與趨勢分析（2018-2030年）
  • 診斷
  • 藥物研發
  • 個人化醫療
  • 疾病風險評估
  • 其他

第6章預測生物標記市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測趨勢分析，2018 年至 2030 年：
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • MEA：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • Thermo Fisher Scientific Inc.
    • Qiagen
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc
    • Agilent Technologies, Inc.
    • Illumina Inc.
    • Merck KGaA
    • Bio-Techne
    • Siemens Healthineers AG
    • PerkinElmer
    • Myriad Genetics, Inc.
    • Becton Dickinson
    • Danaher Corporation
    • Genomic Health, Inc.
    • PacBio
Product Code: GVR-4-68040-593-9

Predictive Biomarkers Market Summary

The global predictive biomarkers market size was estimated at USD 24.30 billion in 2024 and is projected to reach USD 63.54 billion by 2030, growing at a CAGR of 18.02% from 2025 to 2030. The market is experiencing significant growth driven by several factors such as advancements in genomics and precision medicines, increased investment in research and development and rising demand for early detection and personalized treatments.

Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates. Genomics and precision medicine are at the forefront of medical technology, offering the potential for more targeted and effective treatments. Predictive biomarkers for the effects of interventions can reflect an individual's biological constituents ("host characteristics") or traits associated with the disease process or other medical conditions. The NHS and the government are making significant investments in these technologies, including the launch of the NHS Genomic Medicine Service. This service is dedicated to advancements in genomics to benefit patients by implementing genome sequencing, providing molecular diagnostics and genetic testing for cancer patients, and enhancing data integration to facilitate more effective treatments. Moreover, expertise in technology and data analytics with proficiency in developing new sequencing technologies, is

achieved through collaborations that drive innovation and advance precision medicine for instance, in April 2025, Illumnia collaborated with Tempus AI to accelerate adoption of next generation sequencing tests for patients.

The growing investment in research and development (R&D) is a key driver of the predictive biomarkers market. Pharmaceutical companies, biotech firms, and academic institutions are dedicating significant resources to discovering new biomarkers and advancing diagnostic technologies. One prominent application for biomarker identification is next-generation sequencing (NGS), which can rapidly detect millions of DNA copies within a gene. This technology enables comprehensive profiling of multiple genes and mutations in a short amount of time. For example, Illumina's NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of disease. The increasing funding and collaborative efforts in biomarker discovery lead to the development of more effective and accurate predictive tests. This, in turn, is accelerating the growth of the predictive biomarkers market, supporting the next generation of healthcare innovations.

There is an increasing demand for early disease detection and personalized treatments, which is one of the key driver in predictive biomarkers market. Biomarkers provide valuable insights into an individual's health, helping identify diseases in their early stages before symptoms appear. Early detection enables more effective interventions, improving patient outcomes and reducing treatment costs. An important application of predictive biomarkers is in oncology, which demonstrates resistance to treatment that continues to be a leading cause of mortality in breast cancer patients, driving the need for the development of predictive biomarkers.

Innovative approaches, such as omics technologies and artificial intelligence, are being explored to identify highly accurate molecular or imaging biomarkers, with the potential to enhance treatment outcomes. Biomarkers are even gaining popularity incorporation into clinical trials for safety and efficacy tests. Predictive biomarkers may also become a part of these trials tailoring of medicines according to patient needs. As healthcare systems shift toward individualized medicine, predictive biomarkers play a crucial role in optimizing treatment regimens and ensuring the right therapy for each patient.

Global Predictive Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global predictive biomarkers market report on the basis of indication, technology and region.

  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others
  • Technology Outlook (Revenue, USD Million, 2018 - 2030)
  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Others
  • Regional Outlook (Revenue in USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Predictive Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Predictive Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Predictive Biomarkers Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Predictive Biomarkers Market: Indication Movement Analysis
  • 4.3. Predictive Biomarkers Market Size & Trend Analysis, by indication, 2018 to 2030 (USD Million)
  • 4.4. Predictive Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Cancer
    • 4.5.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular Diseases
    • 4.6.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Neurological Diseases
    • 4.7.1. Neurological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Immunological Diseases
    • 4.8.1. Immunological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Predictive Biomarkers Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Predictive Biomarkers Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Diagnostics
    • 5.5.1. Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Drug Discovery & Development
    • 5.6.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Personalized Medicine
    • 5.7.1. Personalized Medicine Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Disease Risk Assessment
    • 5.8.1. Disease Risk Assessment Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Predictive Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. North America: SWOT Analysis
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/Reimbursement
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe: SWOT Analysis
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/Reimbursement
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific: SWOT Analysis
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/Reimbursement
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America: SWOT Analysis
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/Reimbursement
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA: SWOT Analysis
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/Reimbursement
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Thermo Fisher Scientific Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Qiagen
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Bio-Rad Laboratories, Inc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Agilent Technologies, Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Illumina Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Merck KGaA
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Bio-Techne
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Siemens Healthineers AG
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. PerkinElmer
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Myriad Genetics, Inc.
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Services benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Becton Dickinson
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Services benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Danaher Corporation
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Services benchmarking
      • 7.3.16.4. Strategic initiatives
    • 7.3.17. Genomic Health, Inc.
      • 7.3.17.1. Company overview
      • 7.3.17.2. Financial performance
      • 7.3.17.3. Services benchmarking
      • 7.3.17.4. Strategic initiatives
    • 7.3.18. PacBio
      • 7.3.18.1. Company overview
      • 7.3.18.2. Financial performance
      • 7.3.18.3. Services benchmarking
      • 7.3.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Predictive biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 4 North America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 7 Canada Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Canada Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 9 Mexico Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 10 Mexico Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 13 UK Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 14 UK Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 15 Germany Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Germany Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 18 France Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Italy Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 22 Spain Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Denmark Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Denmark Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Sweden Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Sweden Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Norway Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Norway Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 31 Japan Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Japan Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 33 China Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 34 China Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 35 India Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 36 India Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 37 Australia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Australia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 39 South Korea Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 40 South Korea Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 41 Thailand Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Thailand Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Latin America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Latin America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Brazil Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 46 Brazil Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Argentina Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Argentina Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 49 MEA Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 50 MEA Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 51 South Africa Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 52 South Africa Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 55 UAE Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 56 UAE Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Predictive biomarkers market: market outlook
  • Fig. 14 Predictive biomarkers competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Predictive biomarkers market driver impact
  • Fig. 20 Predictive biomarkers market restraint impact
  • Fig. 21 Predictive biomarkers market strategic initiatives analysis
  • Fig. 22 Predictive biomarkers market: Indication movement analysis
  • Fig. 23 Predictive biomarkers market: Indication outlook and key takeaways
  • Fig. 24 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 25 Cardiovascular Diseases market estimates and forecasts,2018 - 2030
  • Fig. 26 Neurological Diseases market estimates and forecasts,2018 - 2030
  • Fig. 27 Immunological Diseases market estimates and forecasts,2018 - 2030
  • Fig. 28 Others market estimates and forecasts,2018 - 2030
  • Fig. 29 Predictive biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 30 Predictive biomarkers Market: Technology movement analysis
  • Fig. 31 Predictive biomarkers market: Technology outlook and key takeaways
  • Fig. 32 Diagnostics market estimates and forecasts, 2018 - 2030
  • Fig. 33 Drug Discovery & Development market estimates and forecasts, 2018 - 2030
  • Fig. 34 Personalized Medicine market estimates and forecasts, 2018 - 2030
  • Fig. 35 Disease Risk Assessment market estimates and forecasts, 2018 - 2030
  • Fig. 36 Others market estimates and forecasts,2018 - 2030
  • Fig. 37 Global Predictive biomarkers market: Regional movement analysis
  • Fig. 38 Global Predictive biomarkers market: Regional outlook and key takeaways
  • Fig. 39 Global Predictive biomarkers market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America, by country
  • Fig. 46 North America
  • Fig. 47 North America market estimates and forecasts, 2018 - 2030
  • Fig. 48 U.S.
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada
  • Fig. 51 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 54 Europe
  • Fig. 55 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 56 UK
  • Fig. 57 UK market estimates and forecasts, 2018 - 2030
  • Fig. 58 Germany
  • Fig. 59 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 60 France
  • Fig. 61 France market estimates and forecasts, 2018 - 2030
  • Fig. 62 Italy
  • Fig. 63 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 64 Spain
  • Fig. 65 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 66 Denmark
  • Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 68 Sweden
  • Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 70 Norway
  • Fig. 71 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 72 Asia Pacific
  • Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 74 China
  • Fig. 75 China market estimates and forecasts, 2018 - 2030
  • Fig. 76 Japan
  • Fig. 77 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 78 India
  • Fig. 79 India market estimates and forecasts, 2018 - 2030
  • Fig. 80 Thailand
  • Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 82 South Korea
  • Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 84 Australia
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 86 Latin America
  • Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 88 Brazil
  • Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 90 Argentina
  • Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 92 Middle East and Africa
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 South Africa
  • Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 96 Saudi Arabia
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 98 UAE
  • Fig. 99 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 100 Kuwait
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 102 Market share of key market players - Predictive biomarkers market